Skip to main content
. 2015 Sep 17;10(9):e0138248. doi: 10.1371/journal.pone.0138248

Fig 3. Patients with del(8)(p21) fail to upregulate pro-apoptotic TRAIL receptor expression upon bortezomib treatment.

Fig 3

Relative expression of TRAIL receptors of 5 MM patients with del(8)(p21) and 7 MM patients without deletion is determined by flow cytometry. Cell surface Expression levels are normalized to corresponding isotype controls. (A) TRAIL-R1, (B) TRAIL-R2, (C) TRAIL-R3, (D) TRAIL-R4. Effect of bortezomib treatment on TRAIL receptor expression is analyzed by paired t-test.